Head of Research, Krungthai XSpring

Waraporn Wiboonkanarak

Head of Research

A full service Thai brokerage

Krungthai XSpring

Krungthai XSpring is a full service broker. The company provides a wide range of investment services such as Securities Brokerage, Derivative Agent Business, Securities Borrowing and Lending, Securities Trading, Underwriting, Financial Advisory, Wealth Advisory, Private Fund Management and International Markets Securities Trading. 

In terms of credibility, Fitch Ratings has assigned Krunghtai XSpring a long-term rating of AA- and a national short-term rating of F1+ with stable outlook.

Equity Bottom-Up

<ul><li>The SET Index is expected to move sideways up, with the resistance at 1,625/1,635 points and the support at 1,610/1,603 points.</li><li>Positive momentum will be generated by i) some good news from the Cabinet meeting concerning measures aimed at boosting the economy, which should be positive to domestic-consumption related stocks and the tourism sector; ii) US housing starts in November, which are expected to continue to slow down, helping to further reduce inflation.</li><li>Meanwhile, the negative momentum may be caused by concerns over a possible US economic recession as a result of the Fed's rate hikes, as well as the increase in the number of COVID-19 infections in China, which has led to school closures in Shanghai.</li></ul>

The SET Index is expected to move sideways up, with the resistance at 1,625/1,635 points and the support at 1,610/1,603 points.Positive momentum will be generated by i) some good news from the Cabinet meeting concerning measures aimed at boosting the economy, which should be positive to domestic-consumption related stocks and the tourism sector; ii) US housing starts in November, which are expected to continue to slow down, helping to further reduce inflation.Meanwhile, the negative momentum may be caused by concerns over a possible US economic recession as a result of the Fed's rate hikes, as well as the increase in the number of COVID-19 infections in China, which has led to school closures in Shanghai.

<ul><li>The SET Index is expected to gain, with the resistance at 1,630/1,649 points and the support at 1,612 points (200-day EMA)/1,607 points (50-day EMA).</li><li>Today's momentum is positive after the US reported October's CPI at +7.7% YoY, below the consensus estimate of 7.9% YoY, while the Republican Party is likely to gain a majority of seats in the House of Representatives.</li><li>The latest Fed Watch Tool shows an 80.6% probability of the Fed hiking interest rates by just 50 bps in the upcoming meeting in December.</li></ul>

The SET Index is expected to gain, with the resistance at 1,630/1,649 points and the support at 1,612 points (200-day EMA)/1,607 points (50-day EMA).Today's momentum is positive after the US reported October's CPI at +7.7% YoY, below the consensus estimate of 7.9% YoY, while the Republican Party is likely to gain a majority of seats in the House of Representatives.The latest Fed Watch Tool shows an 80.6% probability of the Fed hiking interest rates by just 50 bps in the upcoming meeting in December.

Recommendation: Buy on Weakness, Sell on Strength

<ul><li>The SET Index is expected to move sideways up, with the resistance at 1,606/1,614 points (75/200-day EMA) and the support at 1,592/1,588 points.</li><li>We recommend trading buy on AH, NEX and LH.</li><li>Investors have reduced expectations for an interest rate hike of 0.75% by the Fed in December after Fed officials expressed concerns over the adverse impacts of higher rates.</li></ul>

The SET Index is expected to move sideways up, with the resistance at 1,606/1,614 points (75/200-day EMA) and the support at 1,592/1,588 points.We recommend trading buy on AH, NEX and LH.Investors have reduced expectations for an interest rate hike of 0.75% by the Fed in December after Fed officials expressed concerns over the adverse impacts of higher rates.

Krungthai XSpring Zoom Eng. October 26, 2022

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

<p><a href="https://www.smartkarma.com/entities/wuxi-apptec-co-ltd-bf4a1265-beef-48b6-b82d-29308426030f" target="_blank" data-smartkarma-citation="entities:27795:1" rel="noopener">WuXi AppTec Co. Ltd. (2359 HK)</a> has released its financial reports in 2020 and 2021Q1. The revenue in 2020 was RMB16.5 billion, up 28.46% YoY, and net profit attributed to shareholders was RMB2.96 billion, up 59.6% YoY. In 2021Q1, the revenue was RMB4.95 billion, up 55.31% YoY, and net profit attributed to shareholders was RMB1.5 billion, up 394.92% YoY. The results beat market expectations. As the leading/benchmark company in China CRO/CDMO industry, WuXi AppTec has always been the focus of investors. This insight mainly analyzed the performance outlook in the future, including both the certainties and uncertainties. </p>

WuXi AppTec Co. Ltd. (2359 HK) has released its financial reports in 2020 and 2021Q1. The revenue in 2020 was RMB16.5 billion, up 28.46% YoY, and net profit attributed to shareholders was RMB2.96 billion, up 59.6% YoY. In 2021Q1, the revenue was RMB4.95 billion, up 55.31% YoY, and net profit attributed to shareholders was RMB1.5 billion, up 394.92% YoY. The results beat market expectations. As the leading/benchmark company in China CRO/CDMO industry, WuXi AppTec has always been the focus of investors. This insight mainly analyzed the performance outlook in the future, including both the certainties and uncertainties. 

WuXi AppTec (2359.HK) - The Certainties and the Uncertainties

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Kindstar Globalgene Technology / Equity Capital Markets

<p>Kindstar is a leading esoteric test service provider in China. The company has a dominant market in the independent hematological test segment and is looking to raise up to USD 200m in  H-share listing in Hong Kong. </p><p>In our previous note, we discussed Kindstar's business segment. The company has a strong footprint in the hematology test segment with the majority of its revenue is derived from the hematological tests, particularly for lymphoma and myeloma related diseases. The company is relatively weak in other areas such as oncology and maternity related businesses. We think the company can continue to grow the existing pie of hematological tests for which the public hospitals do not want to invest in the test equipment and processes but it will be challenging for the company to expand the business into the area where public hospitals are willing to invest in. We think the company has a decent line-up of investors but there is still a lack of international healthcare investors. The management's experience is also decent.</p><p>In this note, we compare the company's key financial metrics with other leading listed ICL. We also discuss the company's pre-IPO valuation in the context of its growth potential and concerns we raised in our previous note.</p><h2>Our previous coverage on Kindstar</h2><ul><li><a href="https://www.smartkarma.com/insights/kindstar-pre-ipo-issues-with-scalability" target="_blank" rel="noopener">Kindstar (康圣环球) Pre-IPO: Issues with Scalability</a></li></ul>

Kindstar is a leading esoteric test service provider in China. The company has a dominant market in the independent hematological test segment and is looking to raise up to USD 200m in  H-share listing in Hong Kong. In our previous note, we discussed Kindstar's business segment. The company has a strong footprint in the hematology test segment with the majority of its revenue is derived from the hematological tests, particularly for lymphoma and myeloma related diseases. The company is relatively weak in other areas such as oncology and maternity related businesses. We think the company can continue to grow the existing pie of hematological tests for which the public hospitals do not want to invest in the test equipment and processes but it will be challenging for the company to expand the business into the area where public hospitals are willing to invest in. We think the company has a decent line-up of investors but there is still a lack of international healthcare investors. The management's experience is also decent.In this note, we compare the company's key financial metrics with other leading listed ICL. We also discuss the company's pre-IPO valuation in the context of its growth potential and concerns we raised in our previous note.Our previous coverage on KindstarKindstar (康圣环球) Pre-IPO: Issues with Scalability

Kindstar (康圣环球) Pre-IPO: Is It Worth the Premium?

United States

Laboratory Corporation of America Holdings is a clinical laboratory company that offers clinical laboratory tests used by the medical profession in routine testing, patient diagnosis, and in the monitoring and treatment of disease. The Company develops specialty testing operations, such as oncology testing, HIV genotyping and phenotyping, diagnostic genetics and clinical trials.

Laboratory Corporation of America Holdings (LH US)

Laboratory Corporation of America Holdings

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Laboratory Corporation of America Holdings (LH US)

Market Outlook

The SET Index is expected to move sideways up, with the resistance at 1,625/1,635 points and the support at 1,610/1,603 points. Positive momentum...

Krungthai XSpring

Recommendation: Buy on Weakness, Sell on Strength

The SET Index is expected to gain, with the resistance at 1,630/1,649 points and the support at 1,612 points (200-day EMA)/1,607 points (50-day...

Krungthai XSpring

Krungthai XSpring Zoom Eng. October 26, 2022

The SET Index is expected to move sideways up, with the resistance at 1,606/1,614 points (75/200-day EMA) and the support at 1,592/1,588...

Krungthai XSpring

WuXi AppTec (2359.HK) - The Certainties and the Uncertainties

As the benchmark company in China CRO/CDMO industry, WuXi AppTec is always the focus of investors. This insight mainly analyzed the certainties and...

Xinyao (Criss) Wang

Kindstar (康圣环球) Pre-IPO: Is It Worth the Premium?

We compare the company's key financial metrics with other leading listed ICL. We also discuss the company's pre-IPO valuation in the context of its...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)